Timothy Kellett

机构：University of California, San Francisco, University of Colorado Anschutz Medical Campus, University of Montana · ORCID：0009-0000-8585-4299

发表论文 6 篇 · 总被引 65 次 · h-index 5

代表论文

• Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses (2020 · Blood Advances · 被引 37)
• The validation of new CHD1L inhibitors as a therapeutic strategy for cancer (2023 · Biomedicine & Pharmacotherapy · 被引 8)
• HTS discovery of PARP1-HPF1 complex inhibitors in cancer (2023 · SLAS DISCOVERY · 被引 7)
• CHD1L Regulates Cell Survival in Breast Cancer and Its Inhibition by OTI-611 Impedes the DNA Damage Response and Induces PARthanatos (2024 · International Journal of Molecular Sciences · 被引 6)
• CHD1L Inhibitor OTI-611 Synergizes with Chemotherapy to Enhance Antitumor Efficacy and Prolong Survival in Colorectal Cancer Mouse Models (2024 · International Journal of Molecular Sciences · 被引 5)
• Small molecule activation of the tumor suppressor kinase LKB1 (2024 · bioRxiv (Cold Spring Harbor Laboratory) · 被引 2)